Tirzepatide (Brand)
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Tirzepatide is a once-weekly injectable peptide marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. It belongs to the incretin-based class of metabolic medications but is distinct in that it acts on two receptors rather than one.
Unlike GLP-1-only agents such as semaglutide, tirzepatide is a “dual agonist” that engages both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual mechanism has been studied extensively in the SURPASS trials for diabetes and the SURMOUNT trials for weight management.
It is a prescription medication approved by the FDA, not a research-only compound. Both branded products are manufactured by Eli Lilly.
How it works
Tirzepatide mimics two naturally occurring incretin hormones. Activating the GLP-1 receptor enhances insulin release in response to meals, suppresses glucagon, slows gastric emptying, and reduces appetite through effects on the brain. Activating the GIP receptor is thought to complement these actions, contributing to improved insulin sensitivity and appetite regulation.
The combined effect on both pathways is associated in clinical trials with greater improvements in blood sugar control and body weight than GLP-1 receptor agonism alone. The precise contribution of the GIP component in humans is still an area of active research.
Reported benefits
- Studied for significant, sustained reductions in body weight in adults with obesity or overweight
- Studied for improved blood-glucose control and lower HbA1c in type 2 diabetes
- Reported reductions in appetite and food intake
- Associated in trials with improvements in cardiometabolic markers such as blood pressure and lipids
These are outcomes reported in clinical studies of the approved medication and are not guaranteed for any individual.
Considerations & side effects
The most commonly reported side effects are gastrointestinal — nausea, diarrhea, vomiting, and constipation — which are usually most noticeable when beginning treatment or increasing the dose. Less common but more serious risks noted in prescribing information include pancreatitis, gallbladder problems, and a boxed warning regarding thyroid C-cell tumors observed in rodent studies.
Tirzepatide is a prescription medication and should be used under the supervision of a qualified clinician, who can assess eligibility, monitor for side effects, and coordinate it safely with other medications. This page is educational and is not medical advice.
Frequently asked
What is tirzepatide?
It's a once-weekly injectable peptide that activates two gut hormone receptors — GIP and GLP-1 — to lower blood sugar and reduce appetite. It's sold under the brand names Mounjaro and Zepbound.
Is tirzepatide FDA-approved?
Yes. It's approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management in eligible adults. It is a prescription medication.
How is tirzepatide different from semaglutide?
Semaglutide targets only the GLP-1 receptor, while tirzepatide is a dual agonist that also targets the GIP receptor. In a head-to-head diabetes trial, tirzepatide produced greater reductions in blood sugar and body weight.
How is tirzepatide administered?
By subcutaneous injection once weekly, typically in the abdomen, thigh, or upper arm.
What are the most common side effects?
Gastrointestinal effects such as nausea, diarrhea, and constipation are the most frequently reported, and tend to be most noticeable when starting or increasing the dose.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), 2022. ↗
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2), 2021. ↗
- Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials, 2021. ↗
Related compounds
Long-acting amylin receptor agonist for weight management. Combined with semaglutide in CagriSema, showing up to 22.7% weight loss in Phase III trials.
Weight blend combining the amylin analog cagrilintide with the GIP/GLP-1 dual agonist tirzepatide, targeting satiety and glycemic pathways together. No human trial of this exact combination; research-level, sold pre-blended.
Dual-mechanism weight blend pairing the long-acting amylin analog cagrilintide with the GLP-1 agonist semaglutide (1:1). Novo Nordisk's clinical program showed greater weight loss than either component alone. Sold as a single co-lyophilized vial.